The U.S. Supreme Court decided today to consider the patent-eligibility of isolated DNA sequences by reviewing the Federal Circuit’s decision – Ass’n for Molecular Pathology v. Myriad Genetics, Inc., No. 2010-1406 (Fed. Cir. 2012).
Subscribe to This Blog
Topics
- 35 U.S.C. 101
- AIA
- Bioethics
- Bioinformatics
- Biomarkers
- Business Method Patents
- Companion Diagnostics
- Diagnostic Methods
- Economics of Innovation
- FDA
- FDA Guidelines
- Gene Patents
- Genetic Testing
- Genomics
- Genomics and Personalized Medicine Act
- Health Care IT
- Infringement
- Medicare and Medicaid Services
- mHealth
- Patent Reform
- Payor Issues
- Personalized Medicine
- Petitions for Rehearing
- Privacy
- Prometheus
- Reimbursement
- Stem Cells
- UK/EP Patent Cases
- Uncategorized